Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphangioma × mirdametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neurofibromatosis 1 2 Neurofibromatoses 2 Neurofibroma 2 Vascular Malformations 1 Skin Diseases, Vascular 1 Neurofibroma, Plexiform 1 Melanoma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Carcinoma, Non-Small-Cell Lung 1 Arteriovenous Malformations 1

Interventions

mirdametinib 1 Sirolimus 1 Everolimus 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05983159 2026-02-19

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon ⚡